Erlotinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) as first line treatment, in patients with locally advanced/metastatic non small cell lung cancer (NSCLC). A phase II study
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Dec 2009 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov.
- 18 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2009 Biomarkers information updated